Entresto is Novartis AG's key pipeline growth driver, but has had very slow uptake commercially, falling far below early expectations thanks to US market access barriers by payers. Novartis is now confident those hurdles are starting to melt away, prompting the diversified Swiss group to predict that prescription sales of the first-in-class ARNI therapy will triple over the coming year, as the group's sales force is now fully in place and reimbursement coverage in the US is more comprehensive.
Entresto, which combines the neprilysin inhibitor sacubitril with the angiotensin receptor blocker valsartan, accumulated full-year sales of $170m, below the...








